UBS analyst Manav Gupta raised the firm’s price target on Calumet (CLMT) to $13.25 from $12 and keeps a Neutral rating on the shares.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLMT:
- Calumet Specialty Products’ Strong Quarter Amidst Challenges
- Calumet Specialty Products: Strategic Positioning and Operational Improvements Drive Buy Rating
- Calumet Specialty Products: Hold Rating Amid Strategic Positioning and Future Debt Challenges
- Calumet Specialty Products Reports Q2 2025 Results
- Calumet reports Q2 EPS ($1.70) vs. (48c) last year